Innate Pharma

IPHAPhase 2

Marseille, FranceFounded 1999innate-pharma.com

Founded in 1999 by pioneering immunologists, Innate Pharma is a Nasdaq and Euronext-listed biotech focused on harnessing the innate immune system to fight cancer. The company has built a robust pipeline of proprietary and partnered assets, including lacutamab (anti-KIR3DL2), IPH4502 (Nectin-4 ADC), and monalizumab (anti-NKG2A, partnered with AstraZeneca). Its strategy is underpinned by strong scientific foundations, strategic collaborations with major players like AstraZeneca and Sanofi, and a leadership team with deep industry and scientific expertise.

Market Cap

$109.7M

Founded

1999

Focus

AntibodiesBiologics

IPHA · Stock Price

USD 1.172.19 (-65.18%)

Historical price data

AI Company Overview

Technology Platform

Leverages expertise in innate immunity and antibody engineering to develop therapeutic antibodies, including monoclonal antibodies, antibody-drug conjugates (ADCs), and proprietary multi-specific NK cell engagers (ANKET® platform).

Pipeline Snapshot

21 drugs in pipeline

Drug	Indication	Stage
IPH2101	Multiple Myeloma	Phase 2
Lacutamab + Gemcitabine + Oxaliplatine	Peripheral T Cell Lymphoma	Phase 2
IPH5201 + durvalumab + standard chemotherapy	Non Small Cell Lung Cancer	Phase 2
IPH4102	Lymphoma, T-Cell	Phase 2
IPH2101	Smoldering Multiple Myeloma	Phase 2

Funding History

Total raised: $105M

PIPE$50MUndisclosedOct 15, 2015

IPO$45MUndisclosedJun 30, 2006

Series A$10MSofinnova PartnersJun 15, 1999

Opportunities

Significant growth opportunities lie in the successful Phase 3 development and approval of lacutamab for CTCL, a rare disease with high unmet need, and in expanding its novel Nectin-4 ADC (IPH4502) into broader solid tumor indications.

The ANKET® platform partnership with Sanofi provides a pipeline-in-a-product opportunity across multiple targets in both hematology and solid tumors.

Risk Factors

Key risks include clinical trial failures for lead assets, intense competition in the ADC and immuno-oncology spaces, reliance on partners for major programs, and the inherent financial volatility of a clinical-stage biotech dependent on capital markets for funding.

Competitive Landscape

Innate Pharma faces competition from large pharma and biotechs in ADC (e.g., Astellas/Seagen's Padcev) and immuno-oncology, but differentiates through its focus on novel innate immune targets (KIR3DL2, NKG2A) and its proprietary ANKET® NK cell engager platform, which is validated by its major partnership with Sanofi.